| Name | Tolazoline hydrochloride |
| Description | Tolazoline hydrochloride (NSC35110 (hydrochloride)) is a non-selective competitive α-adrenergic receptor antagonist used in treatment of persistent pulmonary hypertension of the newborn. |
| In vivo | In cases of persistent pulmonary hypertension of the newborn (PPHN), Tolazoline acts as a pulmonary vasodilator, effectively reducing pulmonary vascular resistance (PVR) and pulmonary arterial pressure. Additionally, within the human radial artery, Tolazoline blocks α-adrenergic activity, significantly counteracting vascular spasms. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 36 mg/mL (183.04 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (10.17 mM), Sonication is recommended.
DMSO : 55 mg/mL (279.64 mM), Sonication is recommended.
Ethanol : 37 mg/mL (188.12 mM), Sonication is recommended.
|
| Keywords | α-adrenergic receptor | Tolazoline Hydrochloride | Tolazoline hydrochloride | Tolazoline | NSC-35110 | NSC35110 | NSC 35110 | Inhibitor | inhibit | Imidaline Hydrochloride | Imidaline | Beta Receptor | Benzidazol Hydrochloride | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Olanzapine | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Buflomedil hydrochloride | Dexmedetomidine hydrochloride | Phenylephrine hydrochloride | Amitriptyline hydrochloride | Isoprenaline hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Approved Drug Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bitter Compound library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
